Key result
Increasing device-detected AF burden in patients with paroxysmal AF was associated with a dose-response increase in risks of cardiovascular hospitalization, ischemic stroke, and mortality (P<0.001).
Why the study?
Whether the amount of AF patients experience conveys important prognostic information beyond that provided by the diagnosis of AF remains uncertain.
Does increasing device-detected AF burden increase the risk of cardiovascular outcomes in patients with paroxysmal atrial fibrillation and CIEDs?
Cohort
Does increasing device-detected AF burden increase the risk of cardiovascular outcomes in patients with paroxysmal atrial fibrillation and CIEDs?
p-value: p=<0.001
In patients with paroxysmal AF and CIEDs, increasing device-detected AF burden demonstrates a dose-response relationship with higher risks of cardiovascular hospitalization, ischemic stroke, and mortality at 1 and 3 years.
May guide AF burden monitoring in risk stratification; leaves open whether reduction alters outcomes.
BACKGROUND: Whether the amount of atrial fibrillation (AF) patients experience conveys important prognostic information beyond that provided by the diagnosis of AF is uncertain. The study objective was to assess the dose-response relationship between device-detected AF burden and subsequent cardiovascular outcomes. METHODS: Among patients with paroxysmal AF who underwent cardiac implantable electronic device implantation (2010-2016), Merlin.net remote-monitoring data were linked to Medicare claims to assess the magnitude and strength of the associations between device-based AF burden (defined as a daily percentage of time spent in AF or maximal AF episode duration ascertained at baseline over 30 days) and key cardiovascular outcomes. RESULTS: <0.001) There was also a dose-response relationship between increasing AF burden and all-cause or cardiovascular hospitalization and ischemic stroke. Updating AF burden data every 30 days did not alter the AF burden-prognostic relationships determined from the use of baseline data alone. Results were also consistent when 3-year outcomes were considered and after accounting for the use of oral anticoagulants. CONCLUSIONS: In paroxysmal AF, there is a clinically relevant dose-response relationship between increasing AF burden and rates of adverse outcomes at 1- and 3-years, including increasing risks of cardiovascular hospitalization, ischemic stroke, and mortality.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a cohort in Paroxysmal Atrial Fibrillation. Device-detected AF burden vs. Lower AF burden was evaluated on Cardiovascular outcomes (all-cause or cardiovascular hospitalization, ischemic stroke, and mortality) (p=<0.001). Increasing device-detected AF burden in patients with paroxysmal AF was associated with a dose-response increase in risks of cardiovascular hospitalization, ischemic stroke, and mortality (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: